desoximetasone topical spray / Generic mfg. - LARVOL DELTA

A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation. (PubMed, J Drugs Dermatol) - "Desoximetasone 0.25% topical spray is a high to super high range of potency (Class I to Class II) steroid formulation. Given the cosmetic acceptability of spray products, we anticipate that this type of product would be highly effective for the treatment of inflammatory diseases in clinical practice. J Drugs Dermatol. 2017;16(10):972-975."

Journal • Biosimilar

Indian court temporarily stalls Sun Pharma’s Ranbaxy deal (Bloomberg.com) - "An Indian court temporarily stalled Sun Pharmaceutical Industries Ltd. (SUNP)’s $3.2 billion purchase of Ranbaxy Laboratories Ltd. (RBXY) as it considers a petition alleging insider trading....Admitting a writ petition filed by a group of investors seeking a probe by the Securities and Exchange Board of India into any insider trading in Ranbaxy shares,...In the deal announced on April 7, the companies said Ranbaxy investors will get 0.8 share in Sun for every one of their shares, or about 457 rupees."

Anticipated M & A • Corporate lawsuit • Psoriasis

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis (clinicaltrials.gov) - P4; N=129; Completed; Sponsor: Taro Pharmaceuticals USA; Recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Mar 2020

Clinical • Trial completion • Trial completion date • Dermatology • Dermatopathology • Immunology • Pediatrics • Psoriasis

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis (clinicaltrials.gov) - P4; N=100; Recruiting; Sponsor: Taro Pharmaceuticals USA; Trial completion date: Dec 2018 ➔ Dec 2019; Trial primary completion date: Nov 2018 ➔ Nov 2019

Clinical • Trial completion date • Trial primary completion date